# OneTest for Cancer

Source: https://onco.cc/drugs/onetest/  
OnCo record `onetest` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A low-cost blood test from 20/20 BioLabs that measures a panel of protein tumour markers and is sold in the United States as a laboratory test without FDA review.

## Summary

20/20 BioLabs (formerly 20/20 GeneSystems) offers OneTest for Cancer from its CLIA/CAP laboratory in Gaithersburg, Maryland. The company says it screens for multiple cancers including lung, pancreatic, ovarian and liver, without stating a total, and a July 2026 company release states that it has not received FDA De Novo authorisation or premarket approval and is offered as a laboratory-developed test. The company's website gives the price as starting at under $200.

The only peer-reviewed paper found that names the test (Wang et al., Diagnostics 2026) compares capillary and venous blood samples; it is not a study of how well the test finds cancer. No peer-reviewed sensitivity, specificity or positive predictive value for OneTest was found.

## Fields

- Kind: Treatment
- Status: emerging
- Last checked: 2026-10-29
- Tags: test; mced; evidence:insufficient
- Brand: OneTest
- Modality: Multi-cancer blood test (panel of serum tumour-associated proteins)
- Mechanism: A panel of tumour-associated proteins in serum (12 biomarkers in the company's 2026 sampling study) scored by an algorithm with a cancer type prediction.

## Notes

- Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.
- Single protein tumour markers such as CEA and CA-125 are not recommended for screening people without symptoms because they rise in many non-cancer conditions; combining them is the test's premise, and its accuracy in screening has not been published.
- What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening).

## Sources

- 20/20 BioLabs: https://www.2020biolabs.com/
- Wang et al., Diagnostics 2026 (capillary versus venous samples): https://doi.org/10.3390/diagnostics16152324

## Connected records

- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [Proteomics & phosphoproteomics](https://onco.cc/technologies/proteomics/)
- companies: [20/20 BioLabs](https://onco.cc/companies/2020-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/onetest.json